Paul is a computational biologist and writer living in Toronto. He’s been a contributor to Signals for three years, writing articles for the general public about how biotechnology and biomedical research can be used to solve pressing medical problems.
Alongside Paul’s experience in computational biology,
and molecular genetics, he’s interested in how academic research develops into real world, commercial technology, and what’s needed for the Canadian biotech industry needs to grow.
Paul is currently a Post-doctoral Fellow at the Ontario Institute of Cancer Research. Prior to joining the OICR, he worked at the Ottawa Hospital Research Institute and earned a Ph.D. from the University of Ottawa, specializing in computational biology. And finally, Paul earned an H.B.Sc. from the University of Toronto a long time ago.
Paul’s blog can be read at www.checkmatescientist.net
Posts by: Paul
This is part two of a series on Michael West. Read part one. When most people hear of new applications coming out of stem cell research it’s usually via headline grabbing soon-to-be-products like stem cell derived livers, replacement ears, transplantable retinas, among other potentially useful things. Any one of these applications has the chance of…Read more
. Earlier this summer I had the fortunate opportunity to speak with Dr. Michael West, of BioTime, and pick his brain on various aspects of the stem cell industry, what it’s faced, and where it might go. It was a perfect follow up to my post in March that explored BioTime’s acquisition of Geron’s stem…Read more
George Daley (File photo) Immediately after last month’s ISSCR meeting, George Daley travelled to the University of Toronto where he had been invited to be an external reviewer on a PhD thesis defense. While there, Daley spoke to a packed audience interested in what he had to say about cell differentiation. In Boston just days…Read more
. Last week I posted a summary of the first half of a full day Communications for Scientists workshop organized by the Stem Cell Network. This post picks up where I left off, with a description of a “Dragon’s Den” style pitch session intended to introduce trainees to necessary communications skills within a commercialization context. The…Read more
. If Edward Bulwer-Lytton were a biologist two centuries ago, he might have quipped that the pen is mightier than the pipette instead of immortalizing the sword in his expression. Yet phrases emphasizing the power of words have been around for nearly three thousand years and are more relevant to your science than you might…Read more
. As a follow up to last month’s post describing how leaked information about an Alzheimer’s drug clinical trial led to the largest ever case of insider trading and destroyed the careers of Dr. Sidney Gilman, a well-respected clinician, and Matthew Martoma, a young stock trader, the Securities and Exchange Commission has just levied the…Read more
Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some detail last month, and the transaction itself follows a Letter of Intent announced last November, which valued it at approximately $71 million. The transaction leaves Geron to…Read more